INTRODUCTION: To describe the rationale and design of an NIH funded randomized controlled trial: the Patient Activation after DXA Result Notification (PAADRN) study. The aim of this trial is to evaluate the effect that a direct mailing of Dual-Energy X-ray Absorptiometry (DXA) results from bone density testing centers to patients will have on patients' knowledge, treatment and self-efficacy. METHODS: We will enroll approximately 7500 patients presenting for DXA at three study sites, the University of Iowa, the University of Alabama at Birmingham, and Kaiser Permanente of Atlanta, Georgia. We will randomize providers (and their respective patients) to either the intervention arm or usual care. Patients randomized to the intervention group will receive a letter with their DXA results and an educational brochure, while those randomized to usual care will receive their DXA results according to standard practice. The seven discrete outcomes are changes from baseline to 12-weeks and/or 52-weeks post-DXA in: (1) guideline concordant pharmacologic and non-pharmacologic therapy; (2) knowledge of DXA results; (3) osteoporosis-specific knowledge; (4) general health-related quality of life; (5) satisfaction with bone-related health care, (6) patient activation; and, (7) osteoporosis-specific self-efficacy. CONCLUSION: This trial will offer evidence of the impact of a novel approach-direct-to-patient mailing of test results-to improve patient activation in their bone health care. The results will inform clinical practice for the communication of DXA and other test results.
RCT Entities:
INTRODUCTION: To describe the rationale and design of an NIH funded randomized controlled trial: the Patient Activation after DXA Result Notification (PAADRN) study. The aim of this trial is to evaluate the effect that a direct mailing of Dual-Energy X-ray Absorptiometry (DXA) results from bone density testing centers to patients will have on patients' knowledge, treatment and self-efficacy. METHODS: We will enroll approximately 7500 patients presenting for DXA at three study sites, the University of Iowa, the University of Alabama at Birmingham, and Kaiser Permanente of Atlanta, Georgia. We will randomize providers (and their respective patients) to either the intervention arm or usual care. Patients randomized to the intervention group will receive a letter with their DXA results and an educational brochure, while those randomized to usual care will receive their DXA results according to standard practice. The seven discrete outcomes are changes from baseline to 12-weeks and/or 52-weeks post-DXA in: (1) guideline concordant pharmacologic and non-pharmacologic therapy; (2) knowledge of DXA results; (3) osteoporosis-specific knowledge; (4) general health-related quality of life; (5) satisfaction with bone-related health care, (6) patient activation; and, (7) osteoporosis-specific self-efficacy. CONCLUSION: This trial will offer evidence of the impact of a novel approach-direct-to-patient mailing of test results-to improve patient activation in their bone health care. The results will inform clinical practice for the communication of DXA and other test results.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Erin N Marcus; Lee M Sanders; Margaret Pereyra; Yanisa Del Toro; Ada Pat Romilly; Monica Yepes; Monica Webb Hooper; Beth A Jones Journal: J Womens Health (Larchmt) Date: 2011-03-23 Impact factor: 2.681
Authors: Sumit R Majumdar; Jeffrey A Johnson; Finlay A McAlister; Debbie Bellerose; Anthony S Russell; David A Hanley; Don W Morrish; Walter P Maksymowych; Brian H Rowe Journal: CMAJ Date: 2008-02-26 Impact factor: 8.262
Authors: Adrianne Feldstein; Patricia J Elmer; David H Smith; Michael Herson; Eric Orwoll; Chuhe Chen; Mikel Aickin; Martha C Swain Journal: J Am Geriatr Soc Date: 2006-03 Impact factor: 5.562
Authors: Daniel H Solomon; Jennifer M Polinski; Margaret Stedman; Colleen Truppo; Laura Breiner; Catherine Egan; Saira Jan; Minal Patel; Thomas W Weiss; Ya-ting Chen; M Alan Brookhart Journal: J Gen Intern Med Date: 2007-03 Impact factor: 5.128
Authors: Stephanie W Edmonds; Samantha L Solimeo; Vu-Thuy Nguyen; Nicole C Wright; Douglas W Roblin; Kenneth G Saag; Peter Cram Journal: Perm J Date: 2016-11-18
Authors: Nicole C Wright; Mary E Melton; Maira Sohail; Ivan Herbey; Susan Davies; Emily B Levitan; Kenneth G Saag; Natalia V Ivankova Journal: J Racial Ethn Health Disparities Date: 2019-02-11
Authors: S L Solimeo; V-T T Nguyen; S W Edmonds; Y Lou; D W Roblin; K G Saag; P Cram; F D Wolinsky Journal: Osteoporos Int Date: 2019-01-30 Impact factor: 4.507
Authors: F D Wolinsky; S F Hall; Y Lou; S W Edmonds; K G Saag; D W Roblin; N C Wright; M P Jones; P Cram; J R Curtis; S L Morgan; J A Schlechte; J H Williams; D J Zelman Journal: Osteoporos Int Date: 2017-06-15 Impact factor: 4.507
Authors: Peter Cram; Kenneth G Saag; Yiyue Lou; Stephanie W Edmonds; Sylvie F Hall; Douglas W Roblin; Nicole C Wright; Michael P Jones; Fredric D Wolinsky Journal: Med Care Date: 2017-06 Impact factor: 2.983
Authors: Fredric D Wolinsky; Yiyue Lou; Stephanie W Edmonds; Sylvie F Hall; Michael P Jones; Nicole C Wright; Kenneth G Saag; Peter Cram; Douglas W Roblin Journal: J Clin Densitom Date: 2016-09-16 Impact factor: 2.617
Authors: P Cram; F D Wolinsky; Y Lou; S W Edmonds; S F Hall; D W Roblin; N C Wright; M P Jones; K G Saag Journal: Osteoporos Int Date: 2016-06-30 Impact factor: 4.507